标题
Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development
作者
关键词
Immune checkpoint blockade, Immuno-oncology, Combination therapy, Epacadostat, Indoximod, BMS-986205
出版物
Current Oncology Reports
Volume 21, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-01-18
DOI
10.1007/s11912-019-0750-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma
- (2018) Zachary J. Brown et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- IDO1 in cancer: a Gemini of immune checkpoints
- (2018) Lijie Zhai et al. Cellular & Molecular Immunology
- 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells
- (2018) Xiuting Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas
- (2018) Anne Mills et al. MODERN PATHOLOGY
- IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
- (2018) Erik A. Dill et al. MODERN PATHOLOGY
- Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
- (2018) Jae Eun Cheong et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
- (2018) Hatem Soliman et al. Oncotarget
- Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile
- (2018) Annabel Meireson et al. Oncotarget
- Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system
- (2018) Soo Jeong Nam et al. OncoImmunology
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas
- (2018) Maud Toulmonde et al. JAMA Oncology
- Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
- (2018) Asha Nayak-Kapoor et al. Journal for ImmunoTherapy of Cancer
- Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
- (2018) Aung Naing et al. CANCER RESEARCH
- Abstract CT004: Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy
- (2018) Theodore S. Johnson et al. CANCER RESEARCH
- Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
- (2018) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.
- (2018) Timothy Anthony Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.
- (2018) Craig L. Slingluff et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.
- (2018) Nathan Bahary et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical data from the DeCidE1 trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer.
- (2018) Oliver Dorigo et al. JOURNAL OF CLINICAL ONCOLOGY
- Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.
- (2018) Adil Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).
- (2018) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
- (2017) Rebecca Kristeleit et al. GYNECOLOGIC ONCOLOGY
- In situ click chemistry generation of cyclooxygenase-2 inhibitors
- (2017) Atul Bhardwaj et al. Nature Communications
- Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance
- (2017) Marc Hennequart et al. Cancer Immunology Research
- Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
- (2017) Daniel E. Carvajal-Hausdorf et al. Journal for ImmunoTherapy of Cancer
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Next generation predictive biomarkers for immune checkpoint inhibition
- (2016) Yulian Khagi et al. CANCER AND METASTASIS REVIEWS
- STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
- (2016) Henrique Lemos et al. CANCER RESEARCH
- Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies
- (2016) A. M. Monjazeb et al. CLINICAL CANCER RESEARCH
- Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
- (2016) Kurt A. Schalper et al. CLINICAL CANCER RESEARCH
- Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
- (2016) Jon Bjoern et al. CYTOTHERAPY
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- ACTR-53. INTERIM ANALYSIS OF PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY INHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS
- (2016) Yousef Zakharia et al. NEURO-ONCOLOGY
- The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
- (2016) Caroline Jochems et al. Oncotarget
- Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth
- (2016) Yanling Liu et al. Oncotarget
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of immune checkpoint molecules in endometrial carcinoma
- (2015) JIA LIU et al. Experimental and Therapeutic Medicine
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer
- (2015) Mads Duus Hjortsø et al. OncoImmunology
- Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival
- (2015) Debbie M Ferns et al. OncoImmunology
- Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia
- (2015) Valentina Folgiero et al. Oncotarget
- Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma
- (2014) S Han et al. BRITISH JOURNAL OF CANCER
- Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
- (2014) I. Chevolet et al. BRITISH JOURNAL OF DERMATOLOGY
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer
- (2014) Jin Won Kim et al. Gastric Cancer
- Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment
- (2014) Sonia Moretti et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
- (2014) Minghui Li et al. Journal for ImmunoTherapy of Cancer
- Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
- (2013) T. Z. Iversen et al. CLINICAL CANCER RESEARCH
- IDO1 Metabolites Activate β-catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice
- (2013) Ameet I. Thaker et al. GASTROENTEROLOGY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
- (2013) J. Yu et al. JOURNAL OF IMMUNOLOGY
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
- (2013) Ben C. Creelan et al. OncoImmunology
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
- (2011) Maria T Pallotta et al. NATURE IMMUNOLOGY
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
- (2010) J. D. Mezrich et al. JOURNAL OF IMMUNOLOGY
- Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer
- (2010) Katsuhiko Shimizu et al. Journal of Thoracic Oncology
- The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment
- (2009) Greg M. Delgoffe et al. IMMUNITY
- Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
- (2008) Francisco J. Quintana et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search